Cancer Research

Cancer cells
#Combination therapy #Faeth Therapeutics #Oncology #Phase II trial

Preliminary data indicate durable responses for combo cancer therapy 

Faeth Therapeutics has announced topline clinical data from its Phase II trial of PIKTOR, an investigational all-oral combination of serabelisib and sapanisertib, given with paclitaxel.  The drug is being trialled in patients with advanced endometrioid endometrial cancer and a PI3K/AKT/mTOR (PAM) pathway mutation, who had received at… Read More

#Cancer Research #Editor's Choice #News

#Epitopea #Immunotherapy #mRNA #Oncology #Ovarian cancer #Phase I trial

First patient receives mRNA immunotherapy for ovarian cancer

The first patient has been successfully dosed in OVACT, Epitopea’s first-in-human Phase I/Ib clinical trial evaluating its lead programme, CryptiVax-1001, targeting advanced high-grade serous ovarian cancer (HGSOC).  OVACT is designed to evaluate the safety, tolerability, immunogenicity, and early clinical activity of CryptiVax-1001 in HRP+/BRCA-wildtype advanced HGSOC patients. … Read More

#Cancer Research #News #Trending News

#mRNA #Oncology #Phase I trial #Strand Therapeutics

First patients receive mRNA therapy for tumour-selective activation

Strand Therapeutics has dosed the first patients in its ASCENT-1 Phase I clinical trial of STX-003, an intravenously delivered self-replicating mRNA therapy designed to selectively express IL-12 within tumours while restricting expression in healthy tissue.   This is the first clinical evaluation of Strand’s SignalLock genetic circuitry, designed… Read More

#Cancer Research #News

Immunotherapy
#ESMO #Immunotherapy #Oncology #Ovarian cancer #Phase I trial #TILT Biotherapeutics

TILT reports encouraging data at ESMO

Biotechnology company TILT Biotherapeutics has presented encouraging results for its TILT-123 therapy at the European Society for Medical Oncology (ESMO) Congress 2026. The company reported on the Phase Ib portion of its PROTA study, which is evaluating TILT-123 (igrelimogene litadenorepvec) in combination with MSD’s anti-PD-1 therapy Keytruda… Read More

#Cancer Research #News

Gut microbiome
#ESMO #Gut microbiome #Microbiotica #Oncology #Phase I trial

Trial data presented at ESMO support cancer microbiome therapy

Microbiotica has presented clinical data with encouraging efficacy from its Phase Ib MELODY-1 trial of MB097, a precision microbiome therapeutic for patients with advanced melanoma.  The data were presented in a poster at the European Society for Medical Oncology (ESMO) Congress 2026.  The MELODY-1 trial… Read More

#Cancer Research #Editor's Choice #News #Trending News

Cancer tumour
#Collaboration #Georgiamune #Immunotherapy #Menarini #Solid tumours #Stemline Therapeutics

Menarini and Georgiamune sign deal for oral immunotherapy

The Menarini Group and Stemline Therapeutics, a wholly-owned subsidiary of the Menarini Group, have announced an exclusive worldwide license and collaboration agreement with Georgiamune for GIM-621.  GIM-621 is a preclinical-stage first-in-class oral small molecule immunotherapy with potential application across multiple solid tumours.   It is one… Read More

#Business & Investment #Cancer Research #News

Cancer cell
#Breast cancer #ESMO #NEC Bio #Oncology #Phase II trial

NEC presents Phase I/II results for individualised oral neoantigen therapy

NEC Bio has presented results from the Phase I/II TNBC clinical trial of its orally administered individualised neoantigen therapy, NECVAX-NEO1, used in combination with checkpoint inhibitors (CPIs) and chemotherapy for patients with triple-negative breast cancer (TNBC).   The findings were presented in an e-poster at the ESMO Congress… Read More

#Cancer Research #News #Trending News

Monoclonal antibodies
#Colorectal cancer #GSK #Immunotherapy #Monoclonal antibodies #Oncology #US Food and Drug Administration (FDA)

FDA approves first immunotherapy for advanced rectal cancer

The US Food and Drug Administration (FDA) has granted accelerated approval for a new use of the immunotherapy Jemperli (dostarlimab-gxly).  The approval is for Jemperli used alone in adults with previously untreated stage II or stage III locally advanced rectal cancer.  Patients with locally advanced… Read More

#Cancer Research #News #Regulatory #Trending News

#BioNTech #Head and neck cancer #Immunotherapy #mRNA #Phase III trial

BioNTech’s mRNA immunotherapy fails to meet primary endpoint

BioNTech has announced the first topline results from the AHEAD-MERIT Phase II/III clinical trial for its investigational mRNA cancer immunotherapy BNT113 (tenumomeran/raplemomeran or tenu-ra).  The clinical trial is evaluating BNT113 in combination with pembrolizumab compared to pembrolizumab monotherapy as a first-line treatment for patients with unresectable recurrent… Read More

#Cancer Research #News

#Cancer research #Life sciences #London Cancer Hub #Populate #Science and innovation

Populate appoints Director of Science and Innovation 

Populate, a management platform owned by mixed-use developer Socius, has appointed Dr Angela Kukula as Director of Science and Innovation.  Dr Kukula was previously Chief Executive of MedCity and Director of Life Sciences at London & Partners, where she championed London’s life sciences sector on the global… Read More

#Cancer Research #News

Cancer cell
#Breast cancer #Cancer drug targets #Oncology #The Institute of Cancer Research

Breast cancer study uncovers potential new drug target

Scientists have uncovered a previously unknown mechanism that helps breast cancer cells survive the intense stresses of being malignant, revealing a promising new target for future cancer therapies.  A new study has shown that breast cancer cells become highly dependent on a cell membrane protein called GPR89… Read More

#Cancer Research #Editor's Choice #News

CAR-T in multiple myeloma
#CAR-T #Caribou Biosciences #Cell therapy #Haematology #Oncology

Caribou Biosciences cancels allogeneic CAR-T programmes

Caribou Biosciences has announced that it is discontinuing its two allogeneic CAR-T cell therapy programmes due to financing constraints.  It will discontinue development of vispa-cel for the treatment of relapsed or refractory (r/r) B cell non-Hodgkin lymphoma and CB-011 for the treatment of r/r multiple myeloma. … Read More

#Cancer Research #News